KMDA | Ticker Profile - Titan Protect

KMDA

Kamada Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic · NMS

$7.17

Data: 2026-05-15

✓ ETHICAL PASS

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$452M

Total market value of the company

Trailing P/E

22.31

Premium valuation

Forward P/E

12.73

Based on estimated future earnings — lower means cheaper

Rev Growth

+14.5%

Year-over-year revenue change

Profit Margin

11.2%

How much profit the company keeps from each dollar of revenue

ROE

7.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$13.00

+81% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Kamada Ltd.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

https://www.kamada.com

Country: Israel Employees: 462 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

2.5% PASS

Debt must be below 33% of total assets

Cash Ratio

16.6% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$8.89

What our model estimates this business is worth per share

Margin of Safety

19.3%

Slight discount to fair value

Rating

OPPORTUNITY

Overall assessment combining ethics, valuation, and quality

Percentile

99.6th

Ranks in the top 0% of our 13,571 screened universe

Ethical Score

92.7

Valuation Score

77.5

Quality Score

57.3

Combined

N/A

Trading at $8 against a fair value of $9, a 12% discount. Passes all ethical screens. Ranks better than 95% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.829

Good returns relative to risk taken

Kelly Fraction

0.0249

Modest edge detected — smaller position warranted

Calmar Ratio

0.937

Acceptable balance between returns and drawdown risk

Annual Return

27.1%

Historical annualised return based on price data

Max Drawdown

-28.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

231

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.20

Very low correlation to market moves

52W High

$9.35

23% below the year high

52W Low

$6.50

10% above the year low

Avg Volume

62,472

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

0.3%

Low short interest — limited bearish positioning

Div Yield

3.1%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.33

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.04

Conservative use of debt — low financial risk

Current Ratio

4.07

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.20

Like current ratio but excludes inventory — stricter test

Gross Margin

42.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

7.9%

Profit from core operations before interest and tax

Free Cash Flow

$8M

Positive — the business generates more cash than it spends

Revenue (TTM)

$180M

Total revenue over the last 12 months

Net Income

$20M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$15.00

Target Median

$13.00

Target Low

$11.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go